Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment targets Crow's feet and hollow eyes

NCT ID NCT07398755

Symptom relief Sponsor: Yuvell Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study observed 29 adults receiving a combination of botulinum toxin (Letybo), hyaluronic acid filler (Saypha Volume Plus), and polynucleotide injections (Philart Eye) around the eyes. The goal was to see how well this holistic approach reduces wrinkles and restores volume over 22 weeks. Researchers measured skin changes and patient satisfaction at several follow-up visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
botulinum toxin A, hyaluronic acid filler, and polynucleotide
What this could lead to
If successful, this could confirm that a combination of these injectable treatments safely improves wrinkles and volume loss around the eyes for several months.
What could go wrong
This is a small, completed observational study with only 29 participants. Results may not apply to everyone, and the effects are temporary, requiring repeat treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

29 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients visiting the clinic for such a treatment as part of routine clinical practice.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years or older at time of treatment. 2. At least mild periorbital skin wrinkling, mild frown lines at maximum frown and mild. midface volume deficiency as assessed by the investigator 3. Subject has a stable medical condition with no uncontrolled systemic disease. 4. Willingness to participate in the routine follow-up after 8 weeks and 22 weeks and a signed informed consent form. 5. Subject already visiting the clinic for the specific treatment. Exclusion Criteria: 1. Pregnancy and breast feeding. 2. Neuromuscular disease (e.g. myasthenia gravis, Eaton - Lambert syndrome). 3. Known impairment of blood coagulation. 4. Drooping eyelid. 5. Known allergy to botulinum toxin or human albumin (blood protein). 6. Presence of acute infection or inflammation at the proposed injection sites. 7. Botulinum toxin treatment in the glabella within the last 16 weeks. 8. HA- Filler treatment in the midface or periorbital area within the last 6 months. 9. Patients with a history of autoimmune disease or who are receiving immune therapy. 10. History of hypersensitivity to hyaluronic acid, lidocaine hydrochloride or other amidetype local anaesthetics. 11. History of fish product allergy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glabellar lines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glabellar lines Midface volume deficiency Periorbital wrinkling

Contacts and locations

Locations

  • YUVELL

    Vienna, State of Vienna, 1010, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.